BDBM305713 N-((3S,4S)-3-amino-1-(5- (3-cyano-6- ethoxypyrazolo[1,5- a]pyridin-4-yl)pyridin-2- yl)piperidin-4-yl)-5- fluoro-2-methylbenzamide::US10144734, Example 731::US10172845, Example 731::US10441581, Example 731::US10881652, Example 731::US11648243, Example 731

SMILES CCOc1cc(-c2ccc(nc2)N2CC[C@H](NC(=O)c3cc(F)ccc3C)[C@@H](N)C2)c2c(cnn2c1)C#N

InChI Key InChIKey=IJBBCTXYWBKTNT-UHFFFAOYSA-N

Data  15 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 15 hits for monomerid = 305713   

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Array Biopharma

US Patent
LigandPNGBDBM305713(US10144734, Example 731 | N-((3S,4S)-3-amino-1-(5-...)
Affinity DataIC50: 5nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE-TK assay techn...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2019
Entry Details
Go to US Patent

LigandPNGBDBM305713(US10144734, Example 731 | N-((3S,4S)-3-amino-1-(5-...)
Affinity DataIC50: 15nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE-TK assay techn...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2019
Entry Details
Go to US Patent

LigandPNGBDBM305713(US10144734, Example 731 | N-((3S,4S)-3-amino-1-(5-...)
Affinity DataIC50: 27nMAssay Description:The potency of a compound inhibiting G81 OR mutant RET kinase was determined using CisBio's HTRF Kinease-TK assay technology. The assays containe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2019
Entry Details
Go to US Patent

LigandPNGBDBM305713(US10144734, Example 731 | N-((3S,4S)-3-amino-1-(5-...)
Affinity DataIC50: 5nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE-TK assay techn...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/30/2019
Entry Details
Go to US Patent

LigandPNGBDBM305713(US10144734, Example 731 | N-((3S,4S)-3-amino-1-(5-...)
Affinity DataIC50: 15nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE-TK assay techn...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/30/2019
Entry Details
Go to US Patent

LigandPNGBDBM305713(US10144734, Example 731 | N-((3S,4S)-3-amino-1-(5-...)
Affinity DataIC50: 27nMAssay Description:The potency of a compound inhibiting G810R mutant RET kinase was determined using CisBio's HTRF Kinease-TK assay technology. The assays contained...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/30/2019
Entry Details
Go to US Patent

LigandPNGBDBM305713(US10144734, Example 731 | N-((3S,4S)-3-amino-1-(5-...)
Affinity DataIC50: 5nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE-TK assay techn...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/24/2020
Entry Details
Go to US Patent

LigandPNGBDBM305713(US10144734, Example 731 | N-((3S,4S)-3-amino-1-(5-...)
Affinity DataIC50: 15nMAssay Description:The potency of a compound inhibiting G810R mutant RET kinase was determined using CisBio's HTRF Kinease-TK assay technology. The assays contained...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/24/2020
Entry Details
Go to US Patent

LigandPNGBDBM305713(US10144734, Example 731 | N-((3S,4S)-3-amino-1-(5-...)
Affinity DataIC50: 27nMAssay Description:The potency of a compound inhibiting G810R mutant RET kinase was determined using CisBio's HTRF Kinease-TK assay technology. The assays contained...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/24/2020
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Array Biopharma

US Patent
LigandPNGBDBM305713(US10144734, Example 731 | N-((3S,4S)-3-amino-1-(5-...)
Affinity DataIC50: 5nMAssay Description:Wildtype and V804M mutant: Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2021
Entry Details
Go to US Patent

LigandPNGBDBM305713(US10144734, Example 731 | N-((3S,4S)-3-amino-1-(5-...)
Affinity DataIC50: 15nMAssay Description:Wildtype and V804M mutant: Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2021
Entry Details
Go to US Patent

LigandPNGBDBM305713(US10144734, Example 731 | N-((3S,4S)-3-amino-1-(5-...)
Affinity DataIC50: 27nMAssay Description:The potency of a compound inhibiting G81 OR mutant RET kinase was determined using CisBio's HTRF Kinease-TK assay technology. The assays containe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2021
Entry Details
Go to US Patent

LigandPNGBDBM305713(US10144734, Example 731 | N-((3S,4S)-3-amino-1-(5-...)
Affinity DataIC50: 5nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE -TK assay tech...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/19/2023
Entry Details
Go to US Patent

LigandPNGBDBM305713(US10144734, Example 731 | N-((3S,4S)-3-amino-1-(5-...)
Affinity DataIC50: 15nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE -TK assay tech...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/19/2023
Entry Details
Go to US Patent

LigandPNGBDBM305713(US10144734, Example 731 | N-((3S,4S)-3-amino-1-(5-...)
Affinity DataIC50: 27nMAssay Description:The potency of a compound inhibiting G810R mutant RET kinase was determined using CisBio's HTRF Kinease-TK assay technology. The assays contained...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/19/2023
Entry Details
Go to US Patent